LivaNova to Host Satellite Symposium on Advances in Neuromodulation at American Epilepsy Society AES2020 Virtual Event
Company to also share new data via poster presentations
“Many patients have tried six or more anti-epileptic drugs before they receive VNS Therapy, despite evidence demonstrating its ability to improve patient outcomes and lower costs,” said
The symposium, “Updates and Advances in Neuromodulation,” includes the following presentations:
- Delays in the treatment of DRE: Occurrence and consequences - Experience in
Presenter: Prof. Arjune Sen, MA (
Oxon), Ph.D., MRCP, Associate Professor, Consultant Neurologist, University of Oxford/John Radcliffe Hospital, UK2
A longitudinal analysis underscores the health care and economic burden of the current pathway for VNS Therapy patients in
Englandand the need for earlier referral of DRE patients to VNS Therapy.
- Delays in the treatment of DRE: Occurrence and consequences - Experience in the
Sandi K. Lam, MD, MBA, Division Head of Neurosurgery, Ann & Robert Lurie Children’s Hospital, Professor of Neurological Surgery, Northwestern University Feinberg School of Medicine
Neuromodulation therapies like VNS Therapy can reduce health care utilization, and associated costs, on an annual, per-patient basis for patients with DRE. This workshop aims to fill knowledge gaps in the economic penalties of DRE for both the patient and provider.
- Comparison of treatment with VNS, RNS, or DBS for DRE
Robert S. Fisher, MD, Ph.D., a Maslah Saul MD Professor and Director of the Stanford Epilepsy Center
For DRE, various neuromodulation therapies represent key treatment options. This session aims to help physicians become aware of the most current data and the evolving role of neuromodulation therapies as the treatment of DRE has advanced.
- Neuromodulation for Drug-Refractory Epilepsy and Chronic Heart Failure: Targets, Delivery, Composition and Titration
James Udelson, MD, Chief of Cardiology, The CardioVascular Center at Tufts Medical Center, Boston
This session will compare and contrast how VNS Therapy is utilized to treat epilepsy and chronic heart failure (CHF). For CHF, VNS Therapy is meant to improve symptoms, function and quality of life, and to reduce the risk of cardiac death or hospitalization for heart failure.
“We continue to learn together to expand our understanding of the efficacy and role of neurostimulation and VNS Therapy in treating drug-resistant epilepsy, with new horizons in treating heart failure,” said
In addition to the symposium,
- “Vagal Nerve Stimulation in genetic developmental epileptic encephalopathies (DEE): approach in highly specialized centers around the world”
- “CORE-VNS: A Prospective Outcomes Registry of Patients with Drug-Resistant Epilepsy Treated with Vagus Nerve Stimulation Therapy”
- “A Journey into the Unknown: An Ethnographic Examination of Epilepsy Treatment Management in the United States”
Opinions presented during this Industry-Sponsored Satellite Educational Activity are those of the speakers and/or the sponsor and/or the accredited provider of continuing medical education, and are not a reflection of
About VNS Therapy for Epilepsy
VNS Therapy is clinically proven safe and effective for the treatment of drug-resistant epilepsy for adults and children 4 years of age and older. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects one in three people with epilepsy. VNS Therapy has not been evaluated by FDA for use in SRSE or LGS patients specifically. For more information, visit VNSTherapy.com.
INTENDED USE/INDICATIONS –
Epilepsy—The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. Commonly reported side effects are hoarseness, shortness of breath, sore throat and coughing. Side effects typically occur during stimulation and decrease over time. See full safety information at VNSTherapy.com/safety.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, upcoming events and presentations regarding the treatment of drug-resistant epilepsy and heart failure using VNS Therapy. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended
References and notes
1 Chen Z, et al. JAMA Neurol. 2018;75:279–86.
LivaNova PLC Media Contact
VP, Corporate Communications